Science Corp's PRIMA implant restores reading vision in geographic atrophy trial
38 patients with untreatable central blindness from geographic atrophy gained a mean 25.5 letters on an eye chart, clearing the trial's bar as PRIMA now launches commercially across Europe.
Executive Summary
- Science Corporation's PRIMA subretinal implant, tested in a device trial with no phase classification, restored functional reading vision in most patients with geographic atrophy, a form of blindness that previously had no treatment to reverse it.
- The result did more than clear a trial bar: it directly supported a CE mark and a live commercial launch across Europe, moving the program from clinical proof to patient access in the same announcement.
- The disclosure did not detail the surgical implant's safety profile, leaving the tolerability side of the story for regulators and future disclosures to fill in as the company pursues the US market.
- No other program in active development shares PRIMA's brain-computer-interface approach to geographic atrophy; the surrounding field is built on anti-VEGF, complement, and gene-therapy mechanisms that treat disease progression rather than restore vision already lost.
The result
Eighty percent of patients in the trial gained at least 10 ETDRS letters, roughly two lines on a standard eye chart, at 12 months, with a mean improvement of 25.5 letters and a p-value below 0.001. Eighty-four percent of patients reported they could read letters, numbers, or words after losing that ability to geographic atrophy, a form of age-related macular degeneration that destroys the photoreceptors responsible for central sight. "These patients, who had lost their central vision completely, have had it restored and can read letters, numbers, and words," said Frank Holz, lead investigator and Chair of Ophthalmology at University Hospital Bonn. ScienceScience Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of BlindnessJul 22, 2026
The design
The trial, registered as NCT04676854 under the acronym PRIMAvera, enrolled 38 patients in an open-label, single-arm design across sites in Germany, France, Italy, the Netherlands, Spain, and the United Kingdom. The registered primary outcome measure was the proportion of subjects with meaningful improvement in visual acuity. PRIMA pairs a subretinal photovoltaic implant with dedicated glasses, an approach the company frames as a brain-computer interface rather than a drug. The company's disclosure did not report a separate safety or adverse-event tally alongside the vision-gain figures. NCT04676854+1Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMDNCT04676854Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of BlindnessJul 22, 2026
From trial to launch
PRIMA received a CE mark under the European Union Medical Device Regulation from notified body DEKRA, authorizing commercial sale across 30 European countries, and the company said the first commercial implant is expected in Germany. In the United States, PRIMA carries FDA Breakthrough Device designation and Humanitarian Use Device designation, and Science Corporation said it is working with the FDA toward a US launch. Country-specific reimbursement applications and site activations are underway across Europe, the company said. ScienceScience Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of BlindnessJul 22, 2026
Operational context
The trial's primary completion date moved from November 2024 to February 2024 in a February 2023 registry update, and its status shifted to Active, not recruiting the same day as enrollment closed at its 38-patient target. Both changes are consistent with a trial nearing its planned end rather than a sign of trouble. The trial remains formally active more than two years after that primary completion date, with a listed study completion date of March 2029, reflecting extended follow-up rather than a stalled program. NCT04676854Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMDNCT04676854
The competitive field
No competing program targets geographic atrophy with an implanted visual prosthesis; the closest listed trials in the indication use complement inhibitors such as Annexon's ANX007, RNA therapies such as Regeneron's cemdisiran, or small molecules such as Belite Bio's tinlarebant, all aimed at slowing disease progression rather than restoring vision already lost. Genentech's OpRegen, a cell-therapy program for geographic atrophy, and gene-therapy or stem-cell programs in the related indication of retinitis pigmentosa round out the broader field, none of which share PRIMA's device-based mechanism. Because no validated treatment restores central vision once geographic atrophy has caused it, the bar this readout sets is durability: whether the letter gains persist beyond 12 months and hold up as more patients are implanted through the European rollout.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.